Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
University Hospital Case Medical Center
mi
from
Cleveland, OH
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
University Hospital Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
The University of California Irvine
mi
from
Orange, CA
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
Maimonides Medical Center
mi
from
Brooklyn, NY
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
Maimonides Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Perfusion Assessment in Laparoscopic Left Anterior Resection
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
DFCI at Faulkner Hospital
mi
from
Boston, MA
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
DFCI at Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New Hampshire Oncology-Hematology, PA
mi
from
Concord, NH
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New Hampshire Oncology-Hematology, PA
mi
from
Concord, NH
Click here to add this to my saved trials
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Blood and Marrow Transplant Group of Georgia at Northside Hospital
mi
from
Atlanta, GA
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Blood and Marrow Transplant Group of Georgia at Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
A Phase 1b, Open-label, Safety And Tolerability Study Of Oral Mdv3100 In Combination With Docetaxel In Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
A Phase 1b, Open-label, Safety And Tolerability Study Of Oral Mdv3100 In Combination With Docetaxel In Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
A Phase 1b, Open-label, Safety And Tolerability Study Of Oral Mdv3100 In Combination With Docetaxel In Men With Advanced Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
A Phase 1b, Open-label, Safety And Tolerability Study Of Oral Mdv3100 In Combination With Docetaxel In Men With Advanced Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute
mi
from
Stanford, CA
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Samuel Oschin Comprehensive Cancer Institute - Cedars Sinai Medical Center
mi
from
Beverly Hills, CA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Samuel Oschin Comprehensive Cancer Institute - Cedars Sinai Medical Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
St. Joseph Heritage Healthcare
mi
from
Santa Rosa, CA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
St. Joseph Heritage Healthcare
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital of South Bend
mi
from
South Bend, IN
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Medstar Health - Union Memorial Hospital
mi
from
Baltimore, MD
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Medstar Health - Union Memorial Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Medstar Health - Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Medstar Health - Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
MedStar Health - Good Samaritan Hospital
mi
from
Baltimore, MD
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
MedStar Health - Good Samaritan Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Legacy Health, Legacy Good Samaritan Medical Center
mi
from
Portland, OR
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Legacy Health, Legacy Good Samaritan Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Providence Regional Medical Center
mi
from
Everett, WA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Providence Regional Medical Center
mi
from
Everett, WA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated:  12/31/1969
Columbia - St. Mary's
mi
from
Milwaukee, WI
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Status: Enrolling
Updated: 12/31/1969
Columbia - St. Mary's
mi
from
Milwaukee, WI
Click here to add this to my saved trials